Zobrazeno 1 - 10
of 14
pro vyhledávání: '"John P. Veluchamy"'
Autor:
Renée C. G. de Bruin, John P. Veluchamy, Sinéad M. Lougheed, Famke L. Schneiders, Silvia Lopez-Lastra, Roeland Lameris, Anita G. Stam, Zsolt Sebestyen, Jürgen Kuball, Carla F. M. Molthoff, Erik Hooijberg, Rob C. Roovers, James P. Di Santo, Paul M. P. van Bergen en Henegouwen, Henk M. W. Verheul, Tanja D. de Gruijl, Hans J. van der Vliet
Publikováno v:
OncoImmunology, Vol 7, Iss 1 (2018)
Though Vγ9Vδ2-T cells constitute only a small fraction of the total T cell population in human peripheral blood, they play a vital role in tumor defense and are therefore of major interest to explore for cancer immunotherapy. Vγ9Vδ2-T cell-based
Externí odkaz:
https://doaj.org/article/7c5a3a971c7f40ea88934267608977f3
Autor:
John P. Veluchamy, Nina Kok, Hans J. van der Vliet, Henk M. W. Verheul, Tanja D. de Gruijl, Jan Spanholtz
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to i
Externí odkaz:
https://doaj.org/article/64f543aec174413db67dc06b1cfe3add
Autor:
John Pradeep Veluchamy, Jan Spanholtz, Marleen Tordoir, Victor L Thijssen, Daniëlle A M Heideman, Henk M W Verheul, Tanja D de Gruijl, Hans J van der Vliet
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0157830 (2016)
The ability of Natural Killer (NK) cells to kill tumor targets has been extensively studied in various hematological malignancies. However, NK cell therapy directed against solid tumors is still in early development. Epidermal Growth Factor Receptor
Externí odkaz:
https://doaj.org/article/a994ac3f171142b6b452ccff5a5569c6
Autor:
Rob C. Roovers, Erik Hooijberg, Tanja D. de Gruijl, Renée C.G. de Bruin, Jürgen Kuball, John P. Veluchamy, Roeland Lameris, Anita G.M. Stam, James P. Di Santo, Zsolt Sebestyén, Henk M.W. Verheul, Silvia Lopez-Lastra, Famke L. Schneiders, Paul M.P. van Bergen en Henegouwen, Hans J. van der Vliet, Sinéad M. Lougheed, Carla F. M. Molthoff
Publikováno v:
OncoImmunology, 7(1). Taylor and Francis Inc.
de Bruin, R C G, Veluchamy, J P, Lougheed, S M, Schneiders, F L, Lopez-Lastra, S, Lameris, R, Stam, A G, Sebestyen, Z, Kuball, J, Molthoff, C F M, Hooijberg, E, Roovers, R C, Santo, J P D, van Bergen en Henegouwen, P M P, Verheul, H M W, de Gruijl, T D & van der Vliet, H J 2018, ' A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells ', OncoImmunology, vol. 7, no. 1, e1375641 . https://doi.org/10.1080/2162402X.2017.1375641
OncoImmunology, Vol 7, Iss 1 (2018)
OncoImmunology, 7(1), e1375641. Landes Bioscience
OncoImmunology, 7(1):e1375641. Landes Bioscience
de Bruin, R C G, Veluchamy, J P, Lougheed, S M, Schneiders, F L, Lopez-Lastra, S, Lameris, R, Stam, A G, Sebestyen, Z, Kuball, J, Molthoff, C F M, Hooijberg, E, Roovers, R C, Santo, J P D, van Bergen en Henegouwen, P M P, Verheul, H M W, de Gruijl, T D & van der Vliet, H J 2018, ' A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells ', OncoImmunology, vol. 7, no. 1, e1375641 . https://doi.org/10.1080/2162402X.2017.1375641
OncoImmunology, Vol 7, Iss 1 (2018)
OncoImmunology, 7(1), e1375641. Landes Bioscience
OncoImmunology, 7(1):e1375641. Landes Bioscience
Though Vγ9Vδ2-T cells constitute only a small fraction of the total T cell population in human peripheral blood, they play a vital role in tumor defense and are therefore of major interest to explore for cancer immunotherapy. Vγ9Vδ2-T cell-based
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a92e13006f188c100e0d155e189cf4e
https://europepmc.org/articles/PMC5739573/
https://europepmc.org/articles/PMC5739573/
Autor:
Fenna Bohme, John P. Veluchamy, Tanja D. de Gruijl, Hans van Vliet, Jan Spanholtz, María Delso-Vallejo, Nina Kok, Volker Huppert, Ruth Seggewiss-Bernhardt
Publikováno v:
Scientific Reports, 7:43873. Nature Publishing Group
Veluchamy, J P, Delso-Vallejo, M, Kok, N, Bohme, F, Seggewiss-Bernhardt, R, Van Der Vliet, H J, De Gruijl, T D, Huppert, V & Spanholtz, J 2017, ' Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function ', Scientific Reports, vol. 7, 43873 . https://doi.org/10.1038/srep43873
Scientific Reports
Veluchamy, J P, Delso-Vallejo, M, Kok, N, Bohme, F, Seggewiss-Bernhardt, R, Van Der Vliet, H J, De Gruijl, T D, Huppert, V & Spanholtz, J 2017, ' Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function ', Scientific Reports, vol. 7, 43873 . https://doi.org/10.1038/srep43873
Scientific Reports
Advancements in multi-colour fluorescence activated cell sorting (FACS) panel warrant harmonized procedures to obtain comparable data between various laboratories. The intensifying clinical exploration of Natural Killer (NK) cell-based immunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63120cd0d6125521f69e77e4e3331038
https://research.vumc.nl/en/publications/f8de79a6-0ed1-4ac4-9bfa-34c7e6e79b14
https://research.vumc.nl/en/publications/f8de79a6-0ed1-4ac4-9bfa-34c7e6e79b14
Autor:
Hans J. van der Vliet, Tanja D. de Gruijl, Fenna Bohme, Henk M.W. Verheul, Jan Spanholtz, James P. Di Santo, Daniëlle A.M. Heideman, Nina Kok, Silvia Lopez-Lastra, John P. Veluchamy
Publikováno v:
Veluchamy, J P, Lopez-Lastra, S, Spanholtz, J, Bohme, F, Kok, N, Heideman, D A M, Verheul, H M W, Di Santo, J P, de Gruijl, T D & van der Vliet, H J 2017, ' In Vivo efficacy of umbilical cord blood stem cell-derived NK cells in the treatment of metastatic colorectal cancer ', Frontiers in Immunology, vol. 8, no. FEB, 87 . https://doi.org/10.3389/fimmu.2017.00087
Frontiers in Immunology
Frontiers in Immunology, 8(FEB):87. Frontiers Media S.A.
Frontiers in Immunology
Frontiers in Immunology, 8(FEB):87. Frontiers Media S.A.
Therapeutic monoclonal antibodies against the epidermal growth factor receptor (EGFR) act by inhibiting EGFR downstream signaling and by eliciting a natural killer (NK) cell-mediated antitumor response. The IgG1 mAb cetuximab has been used for treatm
Autor:
Marleen Tordoir, Hans J. van der Vliet, Tanja D. de Gruijl, John P. Veluchamy, Daniëlle A.M. Heideman, Jan Spanholtz, Henk M.W. Verheul, Victor L. Thijssen
Publikováno v:
Veluchamy, J P, Spanholtz, J, Tordoir, M, Thijssen, V L, Heideman, D A M, Verheul, H M W, de Gruijl, T D & van der Vliet, H J 2016, ' Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer ', PLoS ONE, vol. 11, no. 6 . https://doi.org/10.1371/journal.pone.0157830
PLoS ONE
PLoS ONE, 11(6). Public Library of Science
PLoS ONE, Vol 11, Iss 6, p e0157830 (2016)
PLoS ONE
PLoS ONE, 11(6). Public Library of Science
PLoS ONE, Vol 11, Iss 6, p e0157830 (2016)
The ability of Natural Killer (NK) cells to kill tumor targets has been extensively studied in various hematological malignancies. However, NK cell therapy directed against solid tumors is still in early development. Epidermal Growth Factor Receptor
Autor:
Nina Kok, John P. Veluchamy, Henk M.W. Verheul, Fenna Bohme, Tanja D. de Gruijl, Jan Spanholtz, Hans J. van der Vliet
Publikováno v:
Journal of Clinical Oncology. 34:e14525-e14525
e14525Background: Resistance to epidermal growth factor receptor (EGFR) targeting therapy is a major limitation in metastatic colorectal cancer (mCRC). Moreover, NK cells in solid tumor patients ar...
Autor:
Daniëlle A.M. Heideman, A. Marijne Heeren, Jan Spanholtz, Jaap D. H. van Eendenburg, Tanja D. de Gruijl, Gemma G. Kenter, Ekaterina S. Jordanova, Henk M.W. Verheul, Hans J. van der Vliet, John P. Veluchamy
Publikováno v:
Journal of Clinical Oncology. 34:e14526-e14526
e14526Background: Cetuximab monotherapy is not effective in epidermal growth factor receptor (EGFR) positive cervical cancer patients. NK cells synergize with cetuximab through antibody dependent c...
Autor:
Muhammad Atif, Linda Barber, Austin G. Kulasekararaj, Judith C. W. Marsh, Nicholas Lea, Steven Best, Francesco Grimaldi, Ghulam J. Mufti, Rosemary Grain, Monica Sen, Victoria Potter, Pilar Perez-Abellan, Antonio Pagliuca, John P. Veluchamy
Publikováno v:
Blood. 126:3129-3129
Mixed T-cell chimerism is frequent and persists despite discontinuation of immunosuppression after hematopoietic stem cell transplantation (HSCT) for severe aplastic anemia (SAA) using the fludarabine, cyclophosphamide and alemtuzumab/campath (FCC) c